These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

71 related items for PubMed ID: 18289146

  • 1. Three cases of schizophrenia for which olanzapine was effective after early acute phase.
    Yamamoto N, Oda T, Inada T.
    Psychiatry Clin Neurosci; 2008 Feb; 62(1):93-7. PubMed ID: 18289146
    [Abstract] [Full Text] [Related]

  • 2. Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus.
    Wu PL, Lane HY, Su KP.
    Psychiatry Clin Neurosci; 2006 Feb; 60(1):115-6. PubMed ID: 16472369
    [No Abstract] [Full Text] [Related]

  • 3. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I, IC-SOHO Study Group.
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [Abstract] [Full Text] [Related]

  • 4. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
    Yang YK, Tarn YH, Wang TY, Liu CY, Laio YC, Chou YH, Lee SM, Chen CC.
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
    [Abstract] [Full Text] [Related]

  • 5. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ.
    BMC Psychiatry; 2005 Jan 13; 5():3. PubMed ID: 15649317
    [Abstract] [Full Text] [Related]

  • 6. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD.
    Schizophr Res; 2008 Jan 13; 98(1-3):8-15. PubMed ID: 17596914
    [Abstract] [Full Text] [Related]

  • 7. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S, Ameen S, Akhtar S.
    J Clin Psychopharmacol; 2008 Feb 13; 28(1):27-31. PubMed ID: 18204337
    [Abstract] [Full Text] [Related]

  • 8. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.
    Am J Psychiatry; 2002 Feb 13; 159(2):255-62. PubMed ID: 11823268
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, May R, Feldman J, Nemeroff CB, Miller AH.
    J Psychiatr Res; 2006 Oct 13; 40(7):669-76. PubMed ID: 16762371
    [Abstract] [Full Text] [Related]

  • 10. The management of psychogeriatric patient.
    Zannino G, Gargiulo A, Lamenza F, Marotta MG, Barzotti T, Silvestri A, Ettorre E, Marigliano V.
    Arch Gerontol Geriatr Suppl; 2004 Oct 13; (9):465-70. PubMed ID: 15207448
    [Abstract] [Full Text] [Related]

  • 11. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
    Villari V, Rocca P, Fonzo V, Montemagni C, Pandullo P, Bogetto F.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb 15; 32(2):405-13. PubMed ID: 17900775
    [Abstract] [Full Text] [Related]

  • 12. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia.
    Akerele E, Levin FR.
    Am J Addict; 2007 Feb 15; 16(4):260-8. PubMed ID: 17661193
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).
    Gareri P, Cotroneo A, Lacava R, Seminara G, Marigliano N, Loiacono A, De Sarro G.
    Arch Gerontol Geriatr Suppl; 2004 Feb 15; (9):207-15. PubMed ID: 15207416
    [Abstract] [Full Text] [Related]

  • 14. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.
    Ren XS, Qian S, Lee AF, Herz L, Miller DR, Kazis LE.
    J Clin Pharm Ther; 2006 Feb 15; 31(1):57-65. PubMed ID: 16476121
    [Abstract] [Full Text] [Related]

  • 15. Atypical antipsychotic drugs in the treatment of delusional parasitosis.
    Mercan S, Altunay IK, Taskintuna N, Ogutcen O, Kayaoğlu S.
    Int J Psychiatry Med; 2007 Feb 15; 37(1):29-37. PubMed ID: 17645196
    [Abstract] [Full Text] [Related]

  • 16. A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.
    Ritchie CW, Chiu E, Harrigan S, MacFarlane S, Mastwyk M, Halliday G, Hustig H, Hall K, Hassett A, O'Connor DW, Opie J, Nagalingam V, Snowdon J, Ames D.
    Int J Geriatr Psychiatry; 2006 Feb 15; 21(2):171-9. PubMed ID: 16416458
    [Abstract] [Full Text] [Related]

  • 17. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
    Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA.
    Am J Psychiatry; 2004 Jun 15; 161(6):985-95. PubMed ID: 15169686
    [Abstract] [Full Text] [Related]

  • 18. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.
    Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, Garcia-Unzueta MT, Amado JA, Vazquez-Barquero JL.
    Schizophr Res; 2008 Feb 15; 99(1-3):13-22. PubMed ID: 18053689
    [Abstract] [Full Text] [Related]

  • 19. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
    Bounthavong M, Okamoto MP.
    J Eval Clin Pract; 2007 Jun 15; 13(3):453-60. PubMed ID: 17518814
    [Abstract] [Full Text] [Related]

  • 20. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S, Agoston T, Tamás T, Zoltán J.
    Neuropsychopharmacol Hung; 2007 Oct 15; 9(3):115-24. PubMed ID: 18399029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.